Literature DB >> 16717206

Revised diagnostic criteria for neuromyelitis optica.

D M Wingerchuk1, V A Lennon, S J Pittock, C F Lucchinetti, B G Weinshenker.   

Abstract

BACKGROUND: The authors previously proposed diagnostic criteria for neuromyelitis optica (NMO) that facilitate its distinction from prototypic multiple sclerosis (MS). However, some patients with otherwise typical NMO have additional symptoms not attributable to optic nerve or spinal cord inflammation or have MS-like brain MRI lesions. Furthermore, some patients are misclassified as NMO by the authors' earlier proposed criteria despite having a subsequent course indistinguishable from prototypic MS. A serum autoantibody marker, NMO-IgG, is highly specific for NMO. The authors propose revised NMO diagnostic criteria that incorporate NMO-IgG status.
METHODS: Using final clinical diagnosis (NMO or MS) as the reference standard, the authors calculated sensitivity and specificity for each criterion and various combinations using a sample of 96 patients with NMO and 33 with MS. The authors used likelihood ratios and logistic regression analysis to develop the most practical and informative diagnostic model.
RESULTS: Fourteen patients with NMO (14.6%) had extra-optic-spinal CNS symptoms. NMO-IgG seropositivity was 76% sensitive and 94% specific for NMO. The best diagnostic combination was 99% sensitive and 90% specific for NMO and consisted of at least two of three elements: longitudinally extensive cord lesion, onset brain MRI nondiagnostic for MS, or NMO-IgG seropositivity.
CONCLUSIONS: The authors propose revised diagnostic criteria for definite neuromyelitis optica (NMO) that require optic neuritis, myelitis, and at least two of three supportive criteria: MRI evidence of a contiguous spinal cord lesion 3 or more segments in length, onset brain MRI nondiagnostic for multiple sclerosis, or NMO-IgG seropositivity. CNS involvement beyond the optic nerves and spinal cord is compatible with NMO.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16717206     DOI: 10.1212/01.wnl.0000216139.44259.74

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  721 in total

Review 1.  Association of neuromyelitis optic (NMO) with autoimmune disorders: report of two cases and review of the literature.

Authors:  Paira Sergio; Benegas Mariana; Ortiz Alberto; Uña Claudia; Rillo Oscar; Mannucci Pablo; Allievi Alberto
Journal:  Clin Rheumatol       Date:  2010-06-11       Impact factor: 2.980

2.  The relevance of animal models in multiple sclerosis research.

Authors:  Aleksandar Denic; Aaron J Johnson; Allan J Bieber; Arthur E Warrington; Moses Rodriguez; Istvan Pirko
Journal:  Pathophysiology       Date:  2011-02

Review 3.  A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis.

Authors:  Christopher Eckstein; Shiv Saidha; Michael Levy
Journal:  J Neurol       Date:  2011-09-20       Impact factor: 4.849

4.  Progressive ascending myelopathy: atypical forms of multiple sclerosis or what else?

Authors:  Viviana Nociti; Anna Paola Batocchi; Marco Luigetti; Amelia Conte; Vita Santa Lorusso; Silvia Roiati; Tommaso Tartaglione; Alessandra Del Grande; Mario Sabatelli
Journal:  J Neurol       Date:  2011-04-22       Impact factor: 4.849

Review 5.  Immune mediated diseases and immune modulation in the neurocritical care unit.

Authors:  Gloria von Geldern; Thomas McPharlin; Kyra Becker
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

6.  Illuminating neuromyelitis optica pathogenesis.

Authors:  Richard M Ransohoff
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-23       Impact factor: 11.205

7.  Pathologic heterogeneity persists in early active multiple sclerosis lesions.

Authors:  Imke Metz; Stephen D Weigand; Bogdan F G Popescu; Josa M Frischer; Joseph E Parisi; Yong Guo; Hans Lassmann; Wolfgang Brück; Claudia F Lucchinetti
Journal:  Ann Neurol       Date:  2014-05-13       Impact factor: 10.422

8.  Acute necrotizing encephalopathy (ANE1): rare autosomal-dominant disorder presenting as acute transverse myelitis.

Authors:  Katharina Wolf; Thomas Schmitt-Mechelke; Spyridon Kollias; Armin Curt
Journal:  J Neurol       Date:  2013-01-18       Impact factor: 4.849

9.  CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions.

Authors:  Enrique Alvarez; Laura Piccio; Robert J Mikesell; Eric C Klawiter; Becky J Parks; Robert T Naismith; Anne H Cross
Journal:  Mult Scler       Date:  2013-01-15       Impact factor: 6.312

10.  The history of neuromyelitis optica.

Authors:  Sven Jarius; Brigitte Wildemann
Journal:  J Neuroinflammation       Date:  2013-01-15       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.